Linda Grais
Linda Grais's purchase track record
Linda Grais has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/15/2023 | CRVS | $25K | -14.2% | -48.9% | +6.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Corvus Pharma Q2 2026 Earnings Call Transcript Released. Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.
Transaction History
| ICLR | ▼ Sell | Open Market | 87 | $14K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 590 | $97K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 97 | $16K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 67 | $11K | 8/11/2026 | View on chart |
| ICLR | ▲ Buy | Option Exercise | 1,732 | — | 8/10/2026 | View on chart |
| CRVS | ▲ Buy | Open Market | 10,000 | $25K | 5/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Icon plc (ICLR) gets new US trial boost and UBS price target update
Icon plc is highlighted by a U.S. Health and Human Services project aimed at speeding up clinical trials, which could improve the pace of its drug development. UBS has lifted its rating to neutral and set a $195 target, reflecting confidence in the company’s prospects. The stock sits near a key support level and shows a mild RSI, indicating moderate purchase pressure. These developments suggest increased attention from analysts and potential for short‑term volatility.
Icon plc (ICLR) gets new US trial boost and UBS price target update. Icon plc is highlighted by a U.S. Health and Human Services project aimed at speeding up clinical trials, which could improve the pace of its drug development. UBS has lifted its rating to neutral and set a $195 target, reflecting confidence in the company’s prospects. The stock sits near a key support level and shows a mild RSI, indicating moderate purchase pressure. These developments suggest increased attention from analysts and potential for short‑term volatility.